Protective Effect of Etanercept in Experimentally Generated Acute Kidney Failure

Objective: Acute renal failure (ARF) is a clinical syndrome that causes a decrease in the glomerular filtration rate and leads to an accumulation of nitrogenous waste products and uremic toxins. This study investigated the protective effect of Etanercept on ARF. Materials and Methods: Experiments were done on Balb-C female mice. Acute renal failure was created with an intraperitoneal folic acid injection. Etanercept was injected with folic acid in doses of 0.7 mg/kg, 3.5 mg/kg, and 7 mg/kg in treatment groups. Blood urea nitrogen levels, creatinine and cystatin-c were measured on the 7th day of the study. The kidneys were examined histologically with hematoxylin-eosin staining and Tunel assay. Results: Etanercept improved kidney morphology damaged by folic acid. The apoptotic index was low, and there was less dilation in the renal tubules in the groups treated with Etanercept. Folic acid increased blood urea nitrogen levels. This increase was decreased gradually with increased doses of Etanercept. There were no differences in creatinine levels in all groups. Conclusion: This study investigated the protective effects of Etanercept in the context of Acute Renal Failure (ARF). The results demonstrated that Etanercept improved kidney morphology damaged by folic acid, reduced the apoptotic index, and gradually decreased elevated blood urea nitrogen levels. Although creatinine levels showed no significant differences among the treatment groups, the findings suggest that Etanercept may hold promise as a potential agent for the treatment of ARF. Further research and clinical studies are warranted to validate its effectiveness and safety in human subjects.